Abstract
Immune checkpoint inhibitor (ICI) therapies have revolutionized the treatment of melanomas. Such approaches harness the patient's immune system to effectively combat cancer. While promising, these treatments can trigger autoimmune reactions and variability in patient response, in addition to presenting high costs. Objective: The aim of this study is to deepen the understanding of the resp…